2026年上半年,中国创新药延续高增长态势。国家药监局数据显示,2026年1~6月,中国创新药对外授权交易共81笔,总额约1100亿美元,已达2025年全年总额的八成,创历史新高。 《每日经济新闻》记者(以下简称每经记者)注意到,从上市公司半年报来看,首付款作为部分企业BD(商务拓展)收入的一部分,让利润表短暂“翻红”。据美国并购后服务机构SRS Acquiom统计,过去9年生物制药领域的BD...
Source Link2026年上半年,中国创新药延续高增长态势。国家药监局数据显示,2026年1~6月,中国创新药对外授权交易共81笔,总额约1100亿美元,已达2025年全年总额的八成,创历史新高。 《每日经济新闻》记者(以下简称每经记者)注意到,从上市公司半年报来看,首付款作为部分企业BD(商务拓展)收入的一部分,让利润表短暂“翻红”。据美国并购后服务机构SRS Acquiom统计,过去9年生物制药领域的BD...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.